The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease

Archives of Medical Research

Volumn 44, Issue 8, 2013, Pages 601-610

  Leurs, Paul ^a   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED OXIDATION PROTEINS PRODUCT; CANCER GROWTH FACTOR; CD36 ANTIGEN; COLLAGEN; ENDOTHELIN 1; FUROSINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PENTOSIDINE; PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

BLOOD LEVEL; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TISSUE LEVEL;

CARDIOVASCULAR DISEASES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MORBIDITY; RECEPTORS, IMMUNOLOGIC; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84889589277     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.11.002     Document Type: Review

References (103)

1. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
2. Keith D.S., Nichols G.A., Gullion C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
3. Park S.H., Stenvinkel P., Lindholm B. Cardiovascular biomarkers in chronic kidney disease. J Renal Nutr 2012, 22:120-127.
4. Nin J.W., Jorsal A., Ferreira I., et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011, 34:442-447.
5. Nakashima A., Carrero J.J., Qureshi A.R., et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:2213-2219.
6. Li J.P., Lu L., Wang L.J., et al. Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure. Clin Biochem 2011, 44:984-988.
7. Furuya R., Kumagai H., Miyata T., et al. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol 2012, 16:421-426.
8. Semba R.D., Fink J.C., Sun K., et al. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr 2009, 48:38-44.
9. Perkins B.A., Rabbani N., Weston A., et al. Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One 2012, 7:e35655.
10. Bohlender J.M., Franke S., Stein G., et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005, 289:F645-F659.
11. Vlassara H., Uribarri J., Ferrucci L., et al. Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons. Semin Nephrol 2009, 29:594-603.
12. Pizzarelli F., Lauretani F., Bandinelli S., et al. Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects. Nephrol Dial Transplant 2009, 24:1197-1205.
13. Fu M.X., Wells-Knecht K.J., Blackledge J.A., et al. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994, 43:676-683.
14. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995, 46:223-234.
15. Baynes J.W. From life to death-the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage. Biogerontology 2000, 1:235-246.
16. Haitoglou C.S., Tsilibary E.C., Brownlee M., et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992, 267:12404-12407.
17. Kass D.A., Shapiro E.P., Kawaguchi M., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464-1470.
18. Throckmorton D.C., Brogden A.P., Min B., et al. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995, 48:111-117.
19. Yan S.D., Schmidt A.M., Anderson G.M., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269:9889-9897.
20. Huttunen H.J., Fages C., Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999, 274:19919-19924.
21. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
22. Puddu A., Sanguineti R., Durante A., et al. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol Vis 2012, 18:2509-2517.
23. Warboys C.M., Toh H.B., Fraser P.A. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci 2009, 50:1319-1328.
24. Asahi K., Ichimori K., Nakazawa H., et al. Nitric oxide inhibits the formation of advanced glycation end products. Kidney Int 2000, 58:1780-1787.
25. Yamamoto Y., Doi T., Kato I., et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann NY Acad Sci 2005, 1043:562-566.
26. Yamamoto Y., Kato I., Doi T., et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001, 108:261-268.
27. Brett J., Schmidt A.M., Yan S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993, 143:1699-1712.
28. Ritthaler U., Deng Y., Zhang Y., et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995, 146:688-694.
29. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
30. Park S., Yoon S.J., Tae H.J., et al. RAGE and cardiovascular disease. Front Biosci 2011, 16:486-497.
31. Neeper M., Schmidt A.M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267:14998-15004.
32. Bucciarelli L.G., Kaneko M., Ananthakrishnan R., et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006, 113:1226-1234.
33. Bucciarelli L.G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
34. Schmidt A.M., Yan S.D., Brett J., et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993, 91:2155-2168.
35. Mori Y., Kosaki A., Kishimoto N., et al. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009, 29:18-24.
36. Yang Z., Yan W.X., Cai H., et al. S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J Allergy Clin Immunol 2007, 119:106-114.
37. Schmidt A.M., Yan S.D., Yan S.F., et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108:949-955.
38. Mahajan N., Malik N., Bahl A., et al. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009, 207:597-602.
39. Han E.C., Cho S.B., Ahn K.J., et al. Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behçet's disease and its association with disease activity: a pilot study. Ann Dermatol 2011, 23:313-320.
40. Nozyński J., Zakliczyński M., Konecka-Mrowka D., et al. Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant 2012, 17:53-61.
41. Bodiga V.L., Eda S.R., Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev 2013.
42. Gugliucci A., Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996, 39:149-160.
43. Miyata T., Ueda Y., Horie K., et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998, 53:416-422.
44. Makita Z., Bucala R., Rayfield E.J., et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994, 343:1519-1522.
45. Sugiyama S., Miyata T., Ueda Y., et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998, 9:1681-1688.
46. Slowik-Zylka D., Safranow K., Dziedziejko V., et al. Association of plasma pentosidine concentrations with renal function in kidney graft recipients. Clin Transplant 2010, 24:839-847.
47. Degenhardt T.P., Grass L., Reddy S., et al. Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997, 52:1064-1067.
48. Furuya R., Kumagai H., Odamaki M., et al. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 2009, 112:c255-c2561.
49. Suliman M.E., Heimbürger O., Bárány P., et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003, 14:1614-1622.
50. Odetti P., Monacelli F., Storace D., et al. Correlation between pentosidine and endothelin-1 in subjects undergoing chronic hemodialysis. Horm Metab Res 2006, 38:817-820.
51. Zhou Y., Yu Z., Jia H., et al. Association of serum pentosidine with arterial stiffness in hemodialysis patients. Artif Organs 2010, 34:193-199.
52. Utescu M.S., Couture V., Mac-Way F., et al. Determinants of progression of aortic stiffness in hemodialysis patients: a prospective longitudinal study. Hypertension 2013, 62:154-160.
53. Suliman M.E., Stenvinkel P., Jogestrand T., et al. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006, 66:418-425.
54. Zoccali C., Mallamaci F., Asahia K., et al. Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 2001, 14:293-298.
55. Pachaly M.A., do Nascimento M.M., Suliman M.E., et al. Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. Blood Purif 2008, 26:204-210.
56. Iwashima Y., Eto M., Hata A., et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2000, 277:368-380.
57. Chmielewski M., Bragfors-Helin A.C., Stenvinkel P., et al. Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. Clin Chim Acta 2010, 411:2079-2082.
58. Stenvinkel P., Lindholm B., Heimbürger M., et al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000, 15:1624-1630.
59. Bates D.O., Harper S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002, 39:225-237.
60. Tammela T., Enholm B., Alitalo K., et al. The biology of vascular endothelial growth factors. Cardiovasc Res 2005, 65:550-563.
61. Guo Q., Carrero J.J., Yu X., et al. Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant 2009, 24:3468-3473.
62. Kosaki A., Hasegawa T., Kimura T., et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2004, 89:5423-5428.
63. Basta G., Sironi A.M., Lazzerini G., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006, 91:4628-4634.
64. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.
65. Zakiyanov O., Kalousová M., Kříha V., et al. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Kidney Blood Press Res 2011, 34:457-464.
66. Kalousová M., Hodková M., Kazderová M., et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006, 47:406-411.
67. Franke S., Müller A., Sommer M., et al. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 2003, 59:88-97.
68. Gohda T., Tanimoto M., Moon J.Y., et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 2008, 81:196-201.
69. Uchiyama-Tanaka Y., Mori Y., Kosaki A., et al. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial 2008, 12:28-32.
70. Tanji N., Markowitz G.S., Fu C., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000, 11:1656-1666.
71. Yoshida K., Yoneda T., Fujimoto K., et al. Pentosidine and its deposition in renal tissue in renal transplantation. Transplant Proc 2005, 37:4266-4272.
72. Sato F., Maruyama S., Hayashi H., et al. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008, 108:c194-c201.
73. Li F., Yang N., Zhang L., et al. Increased expression of toll-like receptor 2 in rat diabetic nephropathy. Am J Nephrol 2010, 32:179-186.
74. Nakayama M., Kawaguchi Y., Yamada K., et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997, 51:182-216.
75. De Vriese A.S., Flyvbjerg A., Mortier S., et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003, 14:2109-2118.
76. Schwenger V., Morath C., Salava A., et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006, 17:199-207.
77. Mortier S., Faict D., Schalkwijk C.G., et al. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004, 66:1257-1265.
78. Nakao A., Nakao K., Takatori Y., et al. Effects of icodextrin peritoneal dialysis solution on the peritoneal membrane in the STZ-induced diabetic rat model with partial nephrectomy. Nephrol Dial Transplant 2010, 25:1479-1488.
79. Sakata N., Noma A., Yamamoto Y., et al. Modification of elastin by pentosidine is associated with the calcification of aortic media in patients with end-stage renal disease. Nephrol Dial Transplant 2003, 18:1601-1609.
80. Nazratun N., Mahmood A.A., Kuppusamy U.R., et al. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med 2006, 11:245-250.
81. Iwasaki Y., Kazama J.J., Yamato H., et al. Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 2011, 48:1260-1267.
82. Mitome J., Yamamoto H., Saito M., et al. Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 2011, 88:521-529.
83. Rodiño-Janeiro B.K., Salgado-Somoza A., Teijeira-Fernández E., et al. Receptor for advanced glycation end-products expression in subcutaneous adipose tissue is related to coronary artery disease. Eur J Endocrinol 2011, 164:529-537.
84. Sell D.R., Monnier V.M. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990, 85:380-384.
85. Sell D.R., Carlson E.C., Monnier V.M. Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetologia 1993, 36:936-941.
86. Meerwaldt R., Hartog J.W., Graaff R., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3687-3693.
87. Genuth S., Sun W., Cleary P., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111.
88. Mulder D.J., Water T.V., Lutgers H.L., et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006, 8:523-535.
89. Meerwaldt R., Graaff R., Oomen P.H., et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004, 47:1324-1330.
90. Lutgers H.L., Graaff R., Links T.P., et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006, 29:2654-2659.
91. McIntyre N.J., Fluck R.J., McIntyre C.W., et al. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 2011, 6:2356-2363.
92. Noordzij M.J., Lefrandt J.D., Graaff R., et al. Dermal factors influencing measurement of skin autofluorescence. Diabetes Technol Ther 2011, 13:165-170.
93. Meerwaldt R., Lutgers H.L., Links T.P., et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007, 30:107-112.
94. Mulder D.J., van Haelst P.L., Gross S., et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2008, 197:217-223.
95. Noordzij M.J., Lefrandt J.D., Loeffen E.A., et al. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging 2012, 28:431-438.
96. Jiang J., Chen P., Chen J., et al. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis. Atherosclerosis 2012, 224:187-194.
97. Tanaka K., Tani Y., Asai J., et al. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Nephrol Dial Transplant 2011, 26:214-220.
98. Ueno H., Koyama H., Fukumoto S., et al. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 2011, 60:453-459.
99. Rauscher F.M., Goldschmidt-Clermont P.J., Davis B.H., et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003, 108:457-463.
100. Zieman S.J., Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004, 64:459-470.
101. Hartog J.W., Voors A.A., Bakker S.J., et al. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007, 9:1146-1155.
102. Hartog J.W., Hummel Y.M., Voors A.A., et al. Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 2008, 14:596-602.
103. Goldin A., Beckman J.A., Schmidt A.M., et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.